TY - JOUR
T1 - Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes
T2 - Genetics core aims, progress, and plans
AU - Saykin, Andrew J.
AU - Shen, Li
AU - Foroud, Tatiana M.
AU - Potkin, Steven G.
AU - Swaminathan, Shanker
AU - Kim, Sungeun
AU - Risacher, Shannon L.
AU - Nho, Kwangsik
AU - Huentelman, Matthew J.
AU - Craig, David W.
AU - Thompson, Paul M.
AU - Stein, Jason L.
AU - Moore, Jason H.
AU - Farrer, Lindsay A.
AU - Green, Robert C.
AU - Bertram, Lars
AU - Jack, Clifford R.
AU - Weiner, Michael W.
N1 - Funding Information:
Data analysis was supported in part by NIA grant R01 AG19771 and Indiana Economic Development Corporation (number 87884 ) to Dr Saykin; NIA P30 AG10133-18S1 to Drs B. Ghetti and Saykin; NIBIB R03 EB008674 and an Indiana CTSI award ( NCRR RR025761 ) to Dr Shen , U01 AG032984 to Dr G. Schellenberg , P20 RR020837 to Dr Potkin , R01 N5059873 to Dr Huentelman , as well as U24 RR021992, P30 AG010129 and K01 AG030514 and a Dana Foundation grant. Samples from the NCRAD , support by U24 AG21886 to Dr Foroud, were used in this study.
PY - 2010/5
Y1 - 2010/5
N2 - The role of the Alzheimer's Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimer's Disease Neuroimaging Initiative. Genome-wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimer's disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. Blood collection for RNA studies is a new direction. Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials.
AB - The role of the Alzheimer's Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimer's Disease Neuroimaging Initiative. Genome-wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimer's disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. Blood collection for RNA studies is a new direction. Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials.
KW - Alzheimer's Disease Neuroimaging Initiative (ADNI)
KW - Alzheimer's disease
KW - Cerebrospinal fluid (CSF)
KW - Copy number variation (CNV)
KW - Genome-wide association studies (GWAS)
KW - Magnetic resonance imaging (MRI)
KW - Mild cognitive impairment (MCI)
UR - http://www.scopus.com/inward/record.url?scp=77954021537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954021537&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2010.03.013
DO - 10.1016/j.jalz.2010.03.013
M3 - Article
C2 - 20451875
AN - SCOPUS:77954021537
SN - 1552-5260
VL - 6
SP - 265
EP - 273
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 3
ER -